Finance 1h ago 1 min read
Telehealth platform Hims & Hers ($HIMS) fell roughly 15% after reporting a first-quarter net loss and issuing guidance that fell short of market expectations. The results reflect mounting pressure on the company's compounded GLP-1 drug business following FDA restrictions on compounded semaglutide, with investors focused on the pace of revenue diversification.